Connor, Clark & Lunn Investment Management (CC&L)’s Immunome IMNM Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio IMNM Stock Details IMNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$254K	Buy	+11,991	New	+$257K	﹤0.01%	1525

Other funds holding IMNM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s IMNM Position: Q2 2026 in Review

Connor, Clark & Lunn Investment Management (CC&L) opened a new position in Immunome (IMNM) in Q2 2026: 11,991 shares worth $254K. The stake represents ﹤0.01% of the portfolio and ranks #1525 among its holdings.

202 funds tracked by Wall St. Rank hold IMNM as of Q2 2026.

Connor, Clark & Lunn Investment Management (CC&L) held 11,991 shares of Immunome worth $254K as of Q2 2026.
Immunome was a new Connor, Clark & Lunn Investment Management (CC&L) position in Q2 2026.
Immunome made up ﹤0.01% of Connor, Clark & Lunn Investment Management (CC&L)'s portfolio in Q2 2026, its #1525 holding.
202 funds tracked by Wall St. Rank held Immunome as of Q2 2026.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2026, filed 13 Aug 2026.